BeOne Medicines (NASDAQ:ONC) Insider Sells $36,900.88 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) insider Titus Ball sold 136 shares of the stock in a transaction on Monday, June 8th. The shares were sold at an average price of $271.33, for a total transaction of $36,900.88. Following the completion of the sale, the insider directly owned 36 shares in the company, valued at approximately $9,767.88. This represents a 79.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Trading Down 1.7%

Shares of ONC traded down $4.56 during midday trading on Wednesday, hitting $263.61. The stock had a trading volume of 291,079 shares, compared to its average volume of 255,249. The stock’s 50 day moving average is $301.03 and its 200 day moving average is $315.60. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. The firm has a market cap of $28.92 billion, a PE ratio of 58.97 and a beta of 0.49. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $239.25 and a 1 year high of $385.22.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. The company had revenue of $1.51 billion during the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. As a group, analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on ONC shares. Barclays boosted their price target on BeOne Medicines from $405.00 to $409.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Wells Fargo & Company began coverage on BeOne Medicines in a research report on Monday, May 4th. They set an “overweight” rating and a $400.00 target price for the company. Wall Street Zen upgraded BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Guggenheim raised their price target on BeOne Medicines from $410.00 to $420.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Finally, Zacks Research upgraded BeOne Medicines from a “hold” rating to a “strong-buy” rating in a report on Thursday, June 4th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, BeOne Medicines has an average rating of “Moderate Buy” and an average price target of $390.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ONC. Bank of America Corp DE bought a new position in BeOne Medicines during the 2nd quarter worth about $67,657,000. Man Group plc bought a new stake in shares of BeOne Medicines in the 2nd quarter valued at about $59,031,000. Capital International Investors boosted its stake in BeOne Medicines by 3.3% in the 3rd quarter. Capital International Investors now owns 5,046,058 shares of the company’s stock worth $1,716,883,000 after purchasing an additional 161,052 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in BeOne Medicines in the 2nd quarter worth approximately $38,337,000. Finally, First Trust Advisors LP boosted its stake in BeOne Medicines by 91.9% in the 1st quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock worth $71,696,000 after purchasing an additional 115,601 shares in the last quarter. 48.55% of the stock is currently owned by institutional investors.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.